Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations
Clinical trial NCT01522469 · COMPLETED
Trial details
- NCT number
- NCT01522469
- Sponsor
- Arog Pharmaceuticals, Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2012-07-01
- Primary completion
- 2014-08-01
- Enrollment
- 14
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.